Navigation Links
Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine),Data Published in Pain Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Javelin Pharmaceuticals, Inc. (AMEX: JAV), a leading developer of novel products for pain control, today announced that its Phase 2 multi-dose study of Rylomine was published in Pain Medicine, the official journal of The American Academy of Pain Medicine. The article, entitled, "Analgesic Efficacy and Safety of Morphine-Chitosan Nasal Solution in Patients with Moderate to Severe Pain Following Orthopedic Surgery", was recently made available online and can found at the following link: http://www.blackwell-synergy.com/toc/pme/0/0?.

"Rylomine is one of three late stage drug development candidates in our pipeline that address large underserved markets for pain management. It employs a patented formulation of intranasal morphine in a simple disposable device that requires no programming or special patient education," said, Dr. Daniel B. Carr, CEO and CMO. "While still in development, Rylomine has potential to become the non-invasive approach of choice for administering intermittent doses of morphine for post-surgical pain in medically supervised settings. Morphine is the reference standard for treatment of post-surgical pain, as well as pain from trauma and diseases including cancer."

Top line data from the first of two pivotal post-surgical Phase 3 clinical trials of Javelin's Rylomine is anticipated this summer.

Orthopedic Surgeries

According to the United States Department of Health and Human Services, orthopedic operations make up approximately 10% (7.4 million) of the 73.4 million ambulatory and in-patient surgical procedures in the United States annually.

About Rylomine

Rylomine (intranasal morphine), is currently in Phase 3 development in the United States, for moderate-to-severe pain in supervised healthcare settings. It employs the patented and proprietary, Chysis(R) drug-delivery platform to adhere and regularize the kinet
'"/>




Page: 1 2 3

Related medicine technology :

1. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/25/2014)... 2014  Depomed, Inc. (NASDAQ: DEPO ) ... year 2014 financial results after the market closes on Wednesday, ... call beginning at 4:30 pm EDT, 1:30 pm PDT to discuss ... by dialing 877-317-6789 ( United States ) ... available via a live webcast on the investor relations ...
(Date:7/25/2014)... MISSION, Kan. , July 25, 2014 /PRNewswire-iReach/ ... , and TCGRx, of Powers Lake, ... exclusive partners in a distribution and co-marketing agreement ... to retail pharmacies throughout the United ... of robotics-based pharmacy management and workflow systems to ...
(Date:7/25/2014)... WOONSOCKET, R.I. , July 25, 2014  CVS ... holding a conference call on Tuesday, August 5, 2014, ... discuss its second quarter 2014 financial results. ... broadcast simultaneously through the Investor Relations portion of the ... the webcast, visit http://info.cvscaremark.com/investors . This webcast will ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3
... YORK , June 21 Pfizer Inc. (NYSE: ... and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® ... leukemia (AML)) in the United States and that it will ... October 15, 2010 . , , ...
... , MONTEREY, Calif. , June 21 ... Cayston delivered by the Altera Nebulizer System versus tobramycin ... aeruginosa , the co-primary endpoint of non-inferiority for mean ... (FEV(1)) percent predicted after 28 days of treatment was ...
Cached Medicine Technology:Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 2Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 4Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 5Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 6PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution 2PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution 3PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution 4
(Date:7/28/2014)... (PRWEB) July 28, 2014 ... "McDonald’s continues to market to a disadvantaged ... Hispanic. They use proven, often offensive, ethnically-slanted ... of people." ('The Tainted Burger." Amazon: ... with Anna Lappe', author and activist who ...
(Date:7/27/2014)... (PRWEB) July 28, 2014 Zensah®, the leader ... offering to include a wrist support . The wrist ... the wrist area. , Lateral and Medial Epicondylitis, more commonly ... condition in which there is inflammation of the tendons attached ... unrelated to wrist pain, the muscles that work the wrist ...
(Date:7/27/2014)... a reliable online supplier of women’s special occasion outfits, has ... on its website. Now, all these charming gowns are provided ... are pleased to add the new fabulous prom dress collection ... who are in need of fashionable special occasion outfits. Each ... our clients will love them. Ladies, just visit our online ...
(Date:7/27/2014)... Bags underneath the eyes is one condition that both ... a range of new products now available from Internet retailers. ... serum review that is now posted for adults to access ... with baggy eyes and how the natural ingredients in some ... also provides a detailed overview of the creams and oils ...
(Date:7/27/2014)... virus (HEV) transmission by blood components indicates that about ... their plasma. The findings, published in The Lancet ... red cells, platelets, and fresh frozen plasma) are likely ... The study retrospectively screened 225 000 individual blood donations ... Sept, 2013 for HEV RNA. 79 donors were found ...
Breaking Medicine News(10 mins):Health News:The Tainted Burger- McDonalds's Franchise Owner's Tale by Author Michael B. Potts Says McDonald's Disproportionately Markets to Minorities--Tedx Video Supports Claim 2Health News:Zensah® Releases New Wrist Support 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... Feb. 3 The Ensign Group, Inc. (Nasdaq: ... into Colorado by acquiring four long-term care facilities in ... a 35-bed skilled nursing facility in Littleton, Arvada Nursing ... Temple Center, a 128-bed skilled nursing facility in Englewood, ...
... DEL MAR, Calif., Feb. 3 Plastic & ... the field, published the remarkable safety record of ... killer blood clots to the lungs (pulmonary embolism ... over the past 16 years! This series included ...
... for online vacuum cleaner reviews. , ... Boise, Idaho (PRWEB) February 3, ... will collaborate with The Carpet and Rug Institute (CRI) to ... "Seal of Approval" designation. , , , , ,The new series seeks ...
... web based user self service & identity management software solution that allows ... accounts easily and securely via a web browser, and ends the need ... ... 3, 2009 -- SysOp Tools, Inc. announced that Password Reset PRO, a ...
... Feb. 3 Beneficiaries enrolled in Medicare Part D ... as the "doughnut hole" were much less likely to ... according to a University of Pittsburgh Graduate School of ... 3 online issue of Health Affairs , raise ...
... in the February issue of the Journal of the ... to 20 minutes with simple surgical exercises prior to an ... skills in surgeons of all experience levels. The researchers found ... surgeons, alertness to a higher level for surgical procedures and ...
Cached Medicine News:Health News:The Ensign Group Expands into Colorado 2Health News:Cosmetic Surgery - No Killer Blood Clots to the Lungs Sans GA, PK Anesthesia Can Save the Day 2Health News:The Housekeeping Channel (HC) and The Carpet and Rug Institute (CRI) Partner on Vacuum Cleaner Reviews 2Health News:The Housekeeping Channel (HC) and The Carpet and Rug Institute (CRI) Partner on Vacuum Cleaner Reviews 3Health News:New Web-Based User Self Service & Identity Management Software for Active Directory takes Security, User Convenience to a Whole New Level 2Health News:New Web-Based User Self Service & Identity Management Software for Active Directory takes Security, User Convenience to a Whole New Level 3Health News:Seniors in Medicare's doughnut hole decrease use of meds 2Health News:Journal of American College of Surgeons study finds warm-up helps surgeons improve performance 2
... the most advanced visual electrodiagnostic system ... of retinal and optic nerve function. ... drives this powerful computer-controlled instrument. With ... pattern stimulation, rapid Ganzfeld flash rate ...
... The Universal Biomedical Amplifier (UBA-4204) ... true DC signal amplification and ... commonly seen amplifier problems of ... saturation. These features make the ...
The STALIF stand-alone anterior lumbar fusion cage is the latest product development from Surgicraft. STALIF is the natural evolution of the Hartshill Horseshoe, which has over 10 years clinical suc...
... PACHETTE 3 will enable eye care professionals ... utilizing improved ultrasound technology. The PACHETT 3 ... algorithm used in all the DGH pachymeters ... DGH Model 555 PACHETTE 3 is capable ...
Medicine Products: